Company: CERO
Filing Date: 2025-01-23
Form Type: 424B3
Source: 0001213900-25-005623
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-23
Form: 424B3
Chunk 3
---
 minimum Market Value of Listed Securities requirement (the “MVLS Requirement”),
the $15 million minimum Market Value of Publicly Held Securities requirement (the “MVPHS Requirement”) and the $1.00 minimum
Bid Price requirement (the “Bid Price Requirement”). All applicable automatic grace periods for regaining compliance for such
requirements have expired. The Company’s Plan includes transferring the listing of its securities to the Nasdaq Capital Market,
which permits companies to satisfy a $2.5 million minimum stockholders’ equity requirement in lieu of the MVLS Requirement, and
a lower $1 million MVPHS Requirement, completing a reverse stock split to regain compliance with the Bid Price Requirement and certain
capital raising activities to attain such $2.5 million of stockholders’ equity.

The Extension is subject
to certain conditions, including that the Company regain compliance with the Bid Price Requirement and apply to transfer the listing
of its securities to the Nasdaq Capital Market by January 22, 2025, as well as the provision of certain information prior to the Extension
Date. The Company effected a reverse stock split at a 100 to 1 ratio prior to the open of trading on January 8, 2025 and the closing
price of its common stock on Nasdaq has been above $1.00 on each trading day following such reverse stock split. The Company expects
to submit the application to transfer the listing of its securities to the Nasdaq Capital Market on the date of this Current Report on
Form 8-K. The Company also intends to provide the information required by the Nasdaq Panel’s decision within the timeframe required
thereby. The Company has made substantial progress towards attainment of at least $2.5 million of stockholders’ equity through
the receipt of proceeds of its committed equity facility and exercises of warrants to purchase shares of preferred stock since its last
balance sheet date of September 30, 2024, and has filed a registration statement under the Securities Act of 1933 for additional capital
raising intended to contribute materially to such stockholders’ equity. Nevertheless, the Company cannot assure its stockholders
that it will be successful in raising capital or in satisfying the minimum stockholders’ equity requirement by the Extension Date.

<div align='center'>1

SIGNATURES</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

|